domperidone has been researched along with Hyperprolactinemia in 31 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Hyperprolactinemia: Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the usefulness of the domperidone test for the difficult diagnosis between functional and tumoral hyperprolactinemia." | 9.10 | Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. ( Azaretzky, M; Boquete, HR; Fideleff, G; Fideleff, HL; Giaccio, AV; Honfi, M; Pujol, AB; Suárez, MG, 2003) |
| "Objectives of this experiment were to determine if the domperidone protocol previously used for gestating gilts can also lead to hyperprolactinemia in growing gilts, and to assess the effects of such a protocol on hormonal status, mammary development and gene expression in mammary and pituitary tissue of gilts at puberty." | 8.02 | Hyperprolactinemia using domperidone in prepubertal gilts: Effects on hormonal status, mammary development and mammary and pituitary gene expression. ( Farmer, C; Palin, MF, 2021) |
| " The dopamine receptor antagonist domperidone can increase circulating prolactin concentrations in pigs, but the ideal dose to achieve sustained hyperprolactinemia remains unknown." | 7.91 | Using domperidone to induce and sustain hyperprolactinemia in late-pregnant gilts. ( Farmer, C; Hovey, RC; Mathews, AT, 2019) |
| " Galactorrhea is a well-known side effect of domperidone, and is usually associated with hyperprolactinemia." | 7.81 | Euprolactinemic galactorrhea secondary to domperidone treatment. ( Berberoglu, M; Demir, AM; Kansu, A; Kuloglu, Z, 2015) |
| "Eighty-four patients (10 male, 74 female) whose investigation of hyperprolactinaemia included a domperidone test and high resolution pituitary MRI." | 7.69 | An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia. ( Bevan, JS; Robb, OJ; Sawers, HA; Shaw, J; Strachan, FM; Walmsley, D, 1997) |
| "We investigated the effect of hyperprolactinemia induced by long-term domperidone treatment (10." | 7.68 | Hyperprolactinemia induced by long-term domperidone treatment does not alter the sensitivity of striatal dopamine receptors. ( DeLucia, R; Dos-Santos, LF; Scavone, C, 1991) |
| "Administration of a dopamine (DA) antagonist, domperidone, increased circulating levels of LH in hyperprolactinaemic-amenorrhoeic women with pituitary microadenomas but not in normal women in the early follicular phase of the menstrual cycle." | 7.67 | Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas. ( Kato, K; Seki, K, 1988) |
| "Treatment with melatonin was 200 μg/100 g, subcutaneously." | 5.91 | Protective effect of exogenous melatonin on testicular histopathology and histomorphometry of adult rats with domperidone-induced hyperprolactinemia. ( da Silva Gomes, JA; da Silva, JV; da Silva, LH; de Araújo Silva, EF; Figueira de Oliveira, ML; Furtado de Carvalho Noya, AGA; Mendes Tenorio, FDCA; Moraes Valença, M; Peixoto Magalhães, C; Tenorio, BM, 2023) |
| "These results suggestthat in PES with prolactinoma the inhibiting dopaminergic tone is increased on the thyrotropic cells and reduced on the lactotropic cells in PES with elevated PRL and that some patients with PES might bear a microprolactinoma in the bottom of the sella which remained undetected by the CT scan." | 5.29 | TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome. ( Attali, JR; Combes, ME; Perret, G; Valensi, P, 1996) |
| "When domperidone was injected at the termination of DA infusion, the postinhibitory increases were significantly enhanced in either PRL-oma or normal subjects." | 5.27 | Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma. ( Goh, M; Hanew, K; Murakami, O; Sasaki, A; Sato, S; Shimizu, Y; Yoshinaga, K, 1985) |
| "The aim of this study was to evaluate the usefulness of the domperidone test for the difficult diagnosis between functional and tumoral hyperprolactinemia." | 5.10 | Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. ( Azaretzky, M; Boquete, HR; Fideleff, G; Fideleff, HL; Giaccio, AV; Honfi, M; Pujol, AB; Suárez, MG, 2003) |
| "On d 90 of gestation, gilts received daily injections of (1) canola oil until d 109 ± 1 of gestation (CTL, n = 18); (2) domperidone (to induce hyperprolactinemia) until d 96 ± 1 of gestation (T7, n = 17) or; (3) domperidone (until d 109 ± 1 of gestation (T20, n = 17)." | 4.31 | Effects of sustained hyperprolactinemia in late gestation on the mammary parenchymal tissue transcriptome of gilts. ( Caron, A; Farmer, C; Palin, MF, 2023) |
| "Objectives of this experiment were to determine if the domperidone protocol previously used for gestating gilts can also lead to hyperprolactinemia in growing gilts, and to assess the effects of such a protocol on hormonal status, mammary development and gene expression in mammary and pituitary tissue of gilts at puberty." | 4.02 | Hyperprolactinemia using domperidone in prepubertal gilts: Effects on hormonal status, mammary development and mammary and pituitary gene expression. ( Farmer, C; Palin, MF, 2021) |
| " The dopamine receptor antagonist domperidone can increase circulating prolactin concentrations in pigs, but the ideal dose to achieve sustained hyperprolactinemia remains unknown." | 3.91 | Using domperidone to induce and sustain hyperprolactinemia in late-pregnant gilts. ( Farmer, C; Hovey, RC; Mathews, AT, 2019) |
| " Galactorrhea is a well-known side effect of domperidone, and is usually associated with hyperprolactinemia." | 3.81 | Euprolactinemic galactorrhea secondary to domperidone treatment. ( Berberoglu, M; Demir, AM; Kansu, A; Kuloglu, Z, 2015) |
| " We hypothesized that inducing hyperprolactinemia in primiparous gilts during late gestation by administering the dopamine antagonist domperidone (DOM) would increase MG epithelial cell proliferation and differentiation, subsequent milk yield, and piglet growth." | 3.79 | Late gestational hyperprolactinemia accelerates mammary epithelial cell differentiation that leads to increased milk yield. ( Hovey, RC; Manjarin, R; McMicking, HF; Trott, JF; Vanklompenberg, MK, 2013) |
| "Inflammatory edema was induced by carrageenan in male rats, and hyperprolactinemia was induced by injections of the dopamine receptor antagonist domperidone." | 3.76 | Acute and chronic stress and the inflammatory response in hyperprolactinemic rats. ( Carvalho-Freitas, MI; Cruz-Casallas, PE; Felicio, LF; Malucelli, BE; Nasello, AG; Ochoa-Amaya, JE, 2010) |
| "We investigated the in vitro effect of domperidone-induced hyperprolactinemia on plasma cytokine concentration and blood leukocyte cytokine production in healthy female volunteers." | 3.70 | Plasma cytokine concentration and the cytokine producing ability of whole blood cell cultures from healthy females with pharmacologically induced hyperprolactinemia. ( Blazícková, S; Horváthová, M; Koska, J; Lackovic, V; Rovenský, J; Veselková, Z; Vigas, M, 1999) |
| "Eighty-four patients (10 male, 74 female) whose investigation of hyperprolactinaemia included a domperidone test and high resolution pituitary MRI." | 3.69 | An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia. ( Bevan, JS; Robb, OJ; Sawers, HA; Shaw, J; Strachan, FM; Walmsley, D, 1997) |
| "We investigated the effect of hyperprolactinemia induced by long-term domperidone treatment (10." | 3.68 | Hyperprolactinemia induced by long-term domperidone treatment does not alter the sensitivity of striatal dopamine receptors. ( DeLucia, R; Dos-Santos, LF; Scavone, C, 1991) |
| "Administration of a dopamine (DA) antagonist, domperidone, increased circulating levels of LH in hyperprolactinaemic-amenorrhoeic women with pituitary microadenomas but not in normal women in the early follicular phase of the menstrual cycle." | 3.67 | Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas. ( Kato, K; Seki, K, 1988) |
| "To verify the diagnostic capacity of some dynamic tests of the prolactin (Prl) secretion, the findings obtained by high-resolution computed tomography (CT) were compared with results obtained from tests using nomifensine (NOM) domperidone (DOM) and thyrotrophin-releasing hormone (TRH) in 72 patients with pathological hyperprolactinaemia." | 3.67 | Comparison between pituitary computed tomographic findings and tests of hypothalamo-pituitary function in 72 patients with hyperprolactinaemia. ( Bianchi, SD; Camanni, F; Ciccarelli, E; Gatti, G; Ghigo, E; Massara, F; Molinatti, GM; Müller, EE, 1986) |
| "The basal prolactin (PRL) levels on five different days, the PRL responses to thyrotropin-releasing hormone and to domperidone, and the thyroid-stimulating hormone (TSH) responses to domperidone were studied in 75 regularly menstruating women and 44 patients with moderate hyperprolactinemia." | 3.67 | Is idiopathic hyperprolactinemia a transitional stage toward prolactinoma? ( Afonso, AM; Ferreira, JM; Pereira, MC; Santos, MA; Sobrinho, LG; Sousa, MF, 1987) |
| " Hyperprolactinaemia produced by treatment with either dopamine antagonists (domperidone or haloperidol) or ovine prolactin was also associated with an impairment of the OT stress response in intact females, whereas domperidone treatment failed to modify the response in ovariectomized (OVX) rats." | 3.67 | Oxytocin responses to stress in lactating and hyperprolactinaemic rats. ( Carter, DA; Lightman, SL, 1987) |
| "A study of the effect of alpha-methyl-1-tryosine (metyrosine) blockade (2 g/d for 2 d) of dopamine (DA) synthesis on the PRL and TSH response to domperidone (DOM) and TRH in normal women and subjects with pathological hyperprolactinaemia is reported." | 3.67 | Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinaemic women after dopamine synthesis blockade. ( Camanni, F; Ghigo, E; Goffi, S; Massara, F; Molinatti, GM, 1985) |
| "Domperidone-treated gilts also received 100 mg of domperidone per os twice daily from days 90 to 93 of gestation." | 2.94 | Effects of sustained hyperprolactinemia in late gestation on mammary development of gilts. ( Caron, A; Cohen, J; Farmer, C; Hovey, RC; Laforest, JP; Palin, MF, 2020) |
| "Hypoglycemia was induced by intravenous insulin injection (0." | 2.70 | Hyperprolactinemia does not influence hypothalamic-pituitary-adrenocortical function during hypoglycemia in women. ( Cervenakova, Z; Imrich, R; Koska, J; Ksinantova, L; Kvetnansky, R; Rovensky, J, 2002) |
| "Treatment with melatonin was 200 μg/100 g, subcutaneously." | 1.91 | Protective effect of exogenous melatonin on testicular histopathology and histomorphometry of adult rats with domperidone-induced hyperprolactinemia. ( da Silva Gomes, JA; da Silva, JV; da Silva, LH; de Araújo Silva, EF; Figueira de Oliveira, ML; Furtado de Carvalho Noya, AGA; Mendes Tenorio, FDCA; Moraes Valença, M; Peixoto Magalhães, C; Tenorio, BM, 2023) |
| "These results suggestthat in PES with prolactinoma the inhibiting dopaminergic tone is increased on the thyrotropic cells and reduced on the lactotropic cells in PES with elevated PRL and that some patients with PES might bear a microprolactinoma in the bottom of the sella which remained undetected by the CT scan." | 1.29 | TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome. ( Attali, JR; Combes, ME; Perret, G; Valensi, P, 1996) |
| "When domperidone was injected at the termination of DA infusion, the postinhibitory increases were significantly enhanced in either PRL-oma or normal subjects." | 1.27 | Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma. ( Goh, M; Hanew, K; Murakami, O; Sasaki, A; Sato, S; Shimizu, Y; Yoshinaga, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (29.03) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 7 (22.58) | 29.6817 |
| 2010's | 4 (12.90) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Palin, MF | 3 |
| Caron, A | 2 |
| Farmer, C | 4 |
| de Araújo Silva, EF | 1 |
| da Silva Gomes, JA | 1 |
| Figueira de Oliveira, ML | 1 |
| Furtado de Carvalho Noya, AGA | 1 |
| Peixoto Magalhães, C | 1 |
| da Silva, JV | 1 |
| da Silva, LH | 1 |
| Tenorio, BM | 1 |
| Moraes Valença, M | 1 |
| Mendes Tenorio, FDCA | 1 |
| Hovey, RC | 3 |
| Cohen, J | 1 |
| Laforest, JP | 1 |
| Mathews, AT | 1 |
| Demir, AM | 1 |
| Kuloglu, Z | 1 |
| Berberoglu, M | 1 |
| Kansu, A | 1 |
| Ochoa-Amaya, JE | 1 |
| Malucelli, BE | 1 |
| Cruz-Casallas, PE | 1 |
| Nasello, AG | 2 |
| Felicio, LF | 2 |
| Carvalho-Freitas, MI | 1 |
| Vanklompenberg, MK | 1 |
| Manjarin, R | 1 |
| Trott, JF | 1 |
| McMicking, HF | 1 |
| Imrich, R | 2 |
| Rovensky, J | 4 |
| Cervenakova, Z | 1 |
| Ksinantova, L | 1 |
| Kvetnansky, R | 1 |
| Koska, J | 3 |
| Fideleff, HL | 1 |
| Azaretzky, M | 1 |
| Boquete, HR | 1 |
| Pujol, AB | 1 |
| Honfi, M | 1 |
| Suárez, MG | 1 |
| Fideleff, G | 1 |
| Giaccio, AV | 1 |
| Pinto, LP | 1 |
| Hanna, FW | 1 |
| Evans, LM | 1 |
| Davies, JS | 1 |
| John, R | 1 |
| Scanlon, MF | 1 |
| Silva, EJ | 1 |
| Zaidan-Dagli, M | 1 |
| Anselmo-Franci, JA | 1 |
| Tibenska, E | 1 |
| Vigas, M | 4 |
| De, S | 1 |
| Taylor, CM | 1 |
| Edwards, L | 1 |
| Klimes, I | 1 |
| Jurcovicová, J | 1 |
| Jezová, D | 1 |
| Buc, M | 1 |
| Lojda, Z | 1 |
| Ruzicková, M | 1 |
| Blazícková, S | 2 |
| Rauová, L | 1 |
| Mistina, T | 1 |
| Lackovic, V | 2 |
| Valensi, P | 1 |
| Combes, ME | 1 |
| Perret, G | 1 |
| Attali, JR | 1 |
| Sawers, HA | 1 |
| Robb, OJ | 1 |
| Walmsley, D | 1 |
| Strachan, FM | 1 |
| Shaw, J | 1 |
| Bevan, JS | 1 |
| Veselková, Z | 1 |
| Horváthová, M | 1 |
| Lu, F | 1 |
| Wu, H | 1 |
| Zhang, K | 1 |
| Li, D | 1 |
| Scavone, C | 1 |
| DeLucia, R | 1 |
| Dos-Santos, LF | 1 |
| Seki, K | 1 |
| Kato, K | 1 |
| Ghigo, E | 3 |
| Ciccarelli, E | 2 |
| Bianchi, SD | 1 |
| Gatti, G | 1 |
| Molinatti, GM | 2 |
| Massara, F | 2 |
| Müller, EE | 1 |
| Camanni, F | 3 |
| Pereira, MC | 1 |
| Sobrinho, LG | 1 |
| Afonso, AM | 1 |
| Ferreira, JM | 1 |
| Santos, MA | 1 |
| Sousa, MF | 1 |
| Nappi, C | 1 |
| Colace, G | 1 |
| Di Renzo, GF | 1 |
| Taglialatela, M | 1 |
| Amoroso, S | 1 |
| Annunziato, L | 1 |
| Montemagno, U | 1 |
| Savino, L | 1 |
| Miola, C | 1 |
| Carter, DA | 1 |
| Lightman, SL | 1 |
| Benfenati, F | 1 |
| Ferretti, C | 1 |
| Cimino, M | 1 |
| Vantini, G | 1 |
| Lipartiti, M | 1 |
| Muccioli, G | 1 |
| Di Carlo, R | 1 |
| Algeri, S | 1 |
| Goffi, S | 1 |
| Hanew, K | 1 |
| Sato, S | 1 |
| Sasaki, A | 1 |
| Goh, M | 1 |
| Shimizu, Y | 1 |
| Murakami, O | 1 |
| Yoshinaga, K | 1 |
6 trials available for domperidone and Hyperprolactinemia
| Article | Year |
|---|---|
Effects of sustained hyperprolactinemia in late gestation on mammary development of gilts.
Topics: Animals; Domperidone; Dopamine Antagonists; Drug Administration Schedule; Female; Hyperprolactinemia | 2020 |
Hyperprolactinemia does not influence hypothalamic-pituitary-adrenocortical function during hypoglycemia in women.
Topics: Adrenal Cortex; Adult; Blood Glucose; Domperidone; Epinephrine; Female; Humans; Hyperprolactinemia; | 2002 |
Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test.
Topics: Adenoma; Adolescent; Child; Domperidone; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; M | 2003 |
Pharmacological hyperprolactinemia attenuates hydrocortisone-induced expression of CD11b on human CD8+ cells in vivo.
Topics: Adult; Antigens, CD; CD11 Antigens; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Domperidone | 2004 |
Effect of domperidone-induced hyperprolactinemia on selected immune parameters in healthy women.
Topics: Adolescent; Adult; Antiemetics; Dipeptidyl Peptidase 4; Domperidone; Female; Humans; Hyperprolactine | 1995 |
Domperidone antagonizes bromoergocriptine--induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women.
Topics: Adult; Bromocriptine; Domperidone; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Na | 1987 |
25 other studies available for domperidone and Hyperprolactinemia
| Article | Year |
|---|---|
Effects of sustained hyperprolactinemia in late gestation on the mammary parenchymal tissue transcriptome of gilts.
Topics: Animals; Domperidone; Female; Hyperprolactinemia; Lactation; Mammary Glands, Animal; Parenchymal Tis | 2023 |
Protective effect of exogenous melatonin on testicular histopathology and histomorphometry of adult rats with domperidone-induced hyperprolactinemia.
Topics: Animals; Domperidone; Hyperprolactinemia; Male; Melatonin; Prolactin; Rats; Testis | 2023 |
Hyperprolactinemia using domperidone in prepubertal gilts: Effects on hormonal status, mammary development and mammary and pituitary gene expression.
Topics: Animals; Domperidone; Female; Gene Expression; Hyperprolactinemia; Lactation; Mammary Glands, Animal | 2021 |
Using domperidone to induce and sustain hyperprolactinemia in late-pregnant gilts.
Topics: Animals; Domperidone; Dose-Response Relationship, Drug; Emulsions; Female; Gestational Age; Hyperpro | 2019 |
Euprolactinemic galactorrhea secondary to domperidone treatment.
Topics: Adolescent; Antiemetics; Domperidone; Female; Galactorrhea; Gastroesophageal Reflux; Humans; Hyperpr | 2015 |
Acute and chronic stress and the inflammatory response in hyperprolactinemic rats.
Topics: Acute Disease; Animals; Carrageenan; Chronic Disease; Cold Temperature; Disease Models, Animal; Domp | 2010 |
Late gestational hyperprolactinemia accelerates mammary epithelial cell differentiation that leads to increased milk yield.
Topics: Animals; Cell Differentiation; Cell Proliferation; Domperidone; Dopamine Antagonists; Epithelial Cel | 2013 |
The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia.
Topics: Adult; Domperidone; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary | 2003 |
Prolactin induces adrenal hypertrophy.
Topics: Adrenal Cortex; Animals; Body Weight; Domperidone; Hyperprolactinemia; Hypertrophy; Organ Size; Rats | 2004 |
Domperidone toxicity in an infant on maintenance haemodialysis.
Topics: Domperidone; Dopamine Antagonists; Galactorrhea; Humans; Hyperprolactinemia; Infant; Kidney Failure, | 2007 |
Hyperprolactinaemia in a patient with cystic fibrosis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antiemetics; Cystic Fibrosis; Domperidone; Drug Combination | 2007 |
Acute elevation of endogenous prolactin does not influence glucose homeostasis in healthy men.
Topics: Adult; Domperidone; Dopamine; Dopamine Antagonists; Glucose; Glucose Tolerance Test; Homeostasis; Hu | 1993 |
TSH and prolactin responses to thyrotropin releasing hormone (TRH) and domperidone in patients with empty sella syndrome.
Topics: Adult; Domperidone; Empty Sella Syndrome; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pit | 1996 |
An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia.
Topics: Adolescent; Adult; Domperidone; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Magnetic R | 1997 |
Plasma cytokine concentration and the cytokine producing ability of whole blood cell cultures from healthy females with pharmacologically induced hyperprolactinemia.
Topics: Adult; Blood Cells; Cells, Cultured; Cytokines; Domperidone; Female; Humans; Hyperprolactinemia | 1999 |
[Domperidone and hyperprolactinemia].
Topics: Adult; Domperidone; Female; Gastrointestinal Agents; Humans; Hyperprolactinemia; Middle Aged; Pituit | 1998 |
Hyperprolactinemia induced by long-term domperidone treatment does not alter the sensitivity of striatal dopamine receptors.
Topics: Animals; Corpus Striatum; Domperidone; Hyperprolactinemia; Male; Prolactin; Rats; Rats, Inbred Strai | 1991 |
Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas.
Topics: Adenoma; Adult; Domperidone; Female; Follicular Phase; Humans; Hyperprolactinemia; Luteinizing Hormo | 1988 |
Comparison between pituitary computed tomographic findings and tests of hypothalamo-pituitary function in 72 patients with hyperprolactinaemia.
Topics: Adenoma; Adolescent; Adult; Domperidone; Female; Humans; Hyperprolactinemia; Hypothalamo-Hypophyseal | 1986 |
Is idiopathic hyperprolactinemia a transitional stage toward prolactinoma?
Topics: Adult; Domperidone; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin; Thyrotropin; | 1987 |
TSH response to domperidone.
Topics: Diagnosis, Differential; Domperidone; Humans; Hyperprolactinemia; Thyrotropin | 1986 |
Oxytocin responses to stress in lactating and hyperprolactinaemic rats.
Topics: Animals; Domperidone; Estradiol; Female; Haloperidol; Hyperprolactinemia; Lactation; Oxytocin; Pregn | 1987 |
Effects of sustained hyperprolactinemia induced by chronic treatment with domperidone on central dopaminergic systems in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Domperidone; Dopamine; Drug Administration | 1986 |
Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinaemic women after dopamine synthesis blockade.
Topics: Adult; alpha-Methyltyrosine; Domperidone; Dopamine; Female; Humans; Hyperprolactinemia; Methyltyrosi | 1985 |
Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma.
Topics: Adenoma; Adolescent; Adult; Domperidone; Dopamine; Female; Humans; Hyperprolactinemia; Male; Pituita | 1985 |